Recent News

• 04.17.2025 - Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
• 03.18.2025 - Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
• 03.17.2025 - 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.10.2025 - Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
• 03.07.2025 - Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
• 03.03.2025 - Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics
• 02.28.2025 - Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Recent Filings

• 04.14.2025 - EFFECT Notice of Effectiveness
• 04.04.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.28.2025 - 8-K Current report
• 03.21.2025 - D Notice of Exempt Offering of Securities
• 03.19.2025 - EFFECT Notice of Effectiveness
• 03.18.2025 - 8-K Current report
• 03.18.2025 - EX-99.1 EX-99.1
• 03.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.17.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.17.2025 - POS AM Post-Effective amendments for registration statement